Seroatlas · Human Serome Atlas

GZMK

Granzyme K

Also known as: GRAK_HUMAN, PRSS, TRYP2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P49863
Gene: GZMK
Ensembl: ENSG00000113088
Chromosome: 5
Canonical length: 264 aa
Protein class: Enzymes, Predicted secreted proteins
Subcellular location: Golgi apparatus
Secretome location: Secreted to blood

OverviewNCBI Gene

This gene product is a member of a group of related serine proteases from the cytoplasmic granules of cytotoxic lymphocytes. Cytolytic T lymphocytes (CTL) and natural killer (NK) cells share the remarkable ability to recognize, bind, and lyse specific target cells. They are thought to protect their host by lysing cells bearing on their surface 'nonself' antigens, usually peptides or proteins resulting from infection by intracellular pathogens. The protein described here lacks consensus sequences for N-glycosylation present in other granzymes. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

264 residues, UniProt reviewed canonical sequence.

>P49863|GZMK
     1  MTKFSSFSLF FLIVGAYMTH VCFNMEIIGG KEVSPHSRPF MASIQYGGHH VCGGVLIDPQ
    61  WVLTAAHCQY RFTKGQSPTV VLGAHSLSKN EASKQTLEIK KFIPFSRVTS DPQSNDIMLV
   121  KLQTAAKLNK HVKMLHIRSK TSLRSGTKCK VTGWGATDPD SLRPSDTLRE VTVTVLSRKL
   181  CNSQSYYNGD PFITKDMVCA GDAKGQKDSC KGDSGGPLIC KGVFHAIVSG GHECGVATKP
   241  GIYTLLTKKY QTWIKSNLVP PHTN

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GZMK can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.3
Highest tissue expression: 93 nTPM

Expression across tissuesHPA

Tissue

lymph node: 93 nTPM
spleen: 29 nTPM
tonsil: 26 nTPM
appendix: 18 nTPM
thymus: 11 nTPM
gallbladder: 11 nTPM

Single-cell type

t-cells: 298 nCPM
nk-cells: 162 nCPM
innate lymphoid cells: 16 nCPM
plasma cells: 7.7 nCPM
neutrophil progenitors: 6.5 nCPM
foveolar cells: 3.9 nCPM

Immune cell

MAIT T-cell: 743 nTPM
NK-cell: 506 nTPM
memory CD8 T-cell: 457 nTPM
gdT-cell: 165 nTPM
memory CD4 T-cell: 101 nTPM
total PBMC: 95 nTPM

Brain region

medulla oblongata: 0.8 nTPM
choroid plexus: 0.5 nTPM
white matter: 0.5 nTPM
cerebral cortex: 0.4 nTPM
spinal cord: 0.4 nTPM
thalamus: 0.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.96
gnomAD pLI: 0.01
gnomAD missense Z: 0.32
DepMap mean gene effect: -0.07
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GZMK as an antibody target. Whether an autoantibody or antibody against GZMK could matter depends on whether native GZMK is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GZMK is annotated at the cell surface, where native GZMK is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label GZMK as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...